Literature DB >> 34083490

Antibody fucosylation predicts disease severity in secondary dengue infection.

Tineke Cantaert1, Jeffrey V Ravetch2, Stylianos Bournazos3, Hoa Thi My Vo4, Veasna Duong5, Heidi Auerswald5, Sowath Ly6, Anavaj Sakuntabhai7,8, Philippe Dussart5.   

Abstract

Although antiviral antibodies generally confer protective functions, antibodies against dengue virus (DENV) are associated with enhanced disease susceptibility. Antibodies can mediate DENV infection of leukocytes via Fcγ receptors, likely contributing to dengue disease pathogenesis. To determine if this mechanism accounts for variable disease severity, we examined Fab and Fc structures of anti-DENV antibodies from patients before and after infection and with variable disease outcomes. Neither antibody titers nor neutralizing activity correlated with disease severity in DENV-infected populations. Rather, DENV infection induced a specific increase in immunoglobulin G1 (IgG1) afucosylation, and the levels of afucosylated IgG1 were predictive of dengue disease severity. Thus, the IgG1 fucosylation status represents a robust prognostic tool for dengue disease, highlighting the key role of the Fc glycan structure in dengue pathogenesis.
Copyright © 2021 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 34083490      PMCID: PMC8262508          DOI: 10.1126/science.abc7303

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  33 in total

Review 1.  IgG Fc Glycosylation in Human Immunity.

Authors:  Taia T Wang
Journal:  Curr Top Microbiol Immunol       Date:  2019       Impact factor: 4.291

2.  Increased risk of autoimmune diseases in dengue patients: A population-based cohort study.

Authors:  Hao-Ming Li; Ying-Kai Huang; Yuan-Chih Su; Chia-Hung Kao
Journal:  J Infect       Date:  2018-05-07       Impact factor: 6.072

3.  Dengue viremia titer, antibody response pattern, and virus serotype correlate with disease severity.

Authors:  D W Vaughn; S Green; S Kalayanarooj; B L Innis; S Nimmannitya; S Suntayakorn; T P Endy; B Raengsakulrach; A L Rothman; F A Ennis; A Nisalak
Journal:  J Infect Dis       Date:  2000-01       Impact factor: 5.226

4.  Increased adaptive immune responses and proper feedback regulation protect against clinical dengue.

Authors:  Etienne Simon-Lorière; Veasna Duong; Ahmed Tawfik; Sivlin Ung; Sowath Ly; Isabelle Casadémont; Matthieu Prot; Noémie Courtejoie; Kevin Bleakley; Philippe Buchy; Arnaud Tarantola; Philippe Dussart; Tineke Cantaert; Anavaj Sakuntabhai
Journal:  Sci Transl Med       Date:  2017-08-30       Impact factor: 17.956

5.  Contrasting associations of polymorphisms in FcγRIIa and DC-SIGN with the clinical presentation of dengue infection in a Mexican population.

Authors:  Cecilia A Noecker; Irma Y Amaya-Larios; Marisol Galeana-Hernández; José Ramos-Castañeda; Ruth A Martínez-Vega
Journal:  Acta Trop       Date:  2014-06-06       Impact factor: 3.112

6.  Association of FcγRIIa Polymorphism with Clinical Outcome of Dengue Infection: First Insight from Pakistan.

Authors:  Saima Naz Mohsin; Saqib Mahmood; Ali Amar; Farkhanda Ghafoor; Syed Mohsin Raza; Mahjabeen Saleem
Journal:  Am J Trop Med Hyg       Date:  2015-08-03       Impact factor: 2.345

7.  Viral Load and Cytokine Response Profile Does Not Support Antibody-Dependent Enhancement in Dengue-Primed Zika Virus-Infected Patients.

Authors:  Ana Carolina Bernardes Terzian; Alessandra Soares Schanoski; Mânlio Tasso de Oliveira Mota; Rafael Alves da Silva; Cássia Fernanda Estofolete; Tatiana Elias Colombo; Paula Rahal; Kathryn A Hanley; Nikos Vasilakis; Jorge Kalil; Maurício Lacerda Nogueira
Journal:  Clin Infect Dis       Date:  2017-10-15       Impact factor: 9.079

8.  Bispecific Anti-HIV-1 Antibodies with Enhanced Breadth and Potency.

Authors:  Stylianos Bournazos; Anna Gazumyan; Michael S Seaman; Michel C Nussenzweig; Jeffrey V Ravetch
Journal:  Cell       Date:  2016-06-16       Impact factor: 41.582

9.  Virus-inclusive single-cell RNA sequencing reveals the molecular signature of progression to severe dengue.

Authors:  Fabio Zanini; Makeda L Robinson; Derek Croote; Malaya Kumar Sahoo; Ana Maria Sanz; Eliana Ortiz-Lasso; Ludwig Luis Albornoz; Fernando Rosso; Jose G Montoya; Leslie Goo; Benjamin A Pinsky; Stephen R Quake; Shirit Einav
Journal:  Proc Natl Acad Sci U S A       Date:  2018-12-07       Impact factor: 11.205

10.  Autoantibody Profiling in Plasma of Dengue Virus-Infected Individuals.

Authors:  Hoa Thi My Vo; Veasna Duong; Sowath Ly; Quan-Zhen Li; Philippe Dussart; Tineke Cantaert
Journal:  Pathogens       Date:  2020-12-18
View more
  15 in total

1.  PD-1 directed immunotherapy alters Tfh and humoral immune responses to seasonal influenza vaccine.

Authors:  Ramin Sedaghat Herati; David A Knorr; Laura A Vella; Luisa Victoria Silva; Lakshmi Chilukuri; Sokratis A Apostolidis; Alexander C Huang; Alexander Muselman; Sasikanth Manne; Oliva Kuthuru; Ryan P Staupe; Sharon A Adamski; Senthil Kannan; Raj K Kurupati; Hildegund C J Ertl; Jeffrey L Wong; Stylianos Bournazos; Suzanne McGettigan; Lynn M Schuchter; Ritesh R Kotecha; Samuel A Funt; Martin H Voss; Robert J Motzer; Chung-Han Lee; Dean F Bajorin; Tara C Mitchell; Jeffrey V Ravetch; E John Wherry
Journal:  Nat Immunol       Date:  2022-07-28       Impact factor: 31.250

2.  Cryo-EM structures of human fucosidase FucA1 reveal insight into substrate recognition and catalysis.

Authors:  Zachary Armstrong; Richard W Meek; Liang Wu; James N Blaza; Gideon J Davies
Journal:  Structure       Date:  2022-07-29       Impact factor: 5.871

Review 3.  Passive Immunotherapy Against SARS-CoV-2: From Plasma-Based Therapy to Single Potent Antibodies in the Race to Stay Ahead of the Variants.

Authors:  William R Strohl; Zhiqiang Ku; Zhiqiang An; Stephen F Carroll; Bruce A Keyt; Lila M Strohl
Journal:  BioDrugs       Date:  2022-04-27       Impact factor: 7.744

4.  There Is Strength in Numbers: Quantitation of Fc Gamma Receptors on Murine Tissue-Resident Macrophages.

Authors:  Christof Vorsatz; Niklas Friedrich; Falk Nimmerjahn; Markus Biburger
Journal:  Int J Mol Sci       Date:  2021-11-10       Impact factor: 5.923

5.  A functional spleen contributes to afucosylated IgG in humans.

Authors:  Iwona Wojcik; David E Schmidt; David Falck; Gestur Vidarsson; Lisa A de Neef; Minke A E Rab; Bob Meek; Okke de Weerdt; Manfred Wuhrer; C Ellen van der Schoot; Jaap J Zwaginga; Masja de Haas
Journal:  Sci Rep       Date:  2021-12-15       Impact factor: 4.379

6.  Cross-species higher sensitivities of FcγRIIIA/FcγRIV to afucosylated IgG for enhanced ADCC.

Authors:  Changchuin Mao; Richard Near; Xuemei Zhong; Wenda Gao
Journal:  Antib Ther       Date:  2021-08-19

Review 7.  Building a better antibody through the Fc: advances and challenges in harnessing antibody Fc effector functions for antiviral protection.

Authors:  Bronwyn M Gunn; Shuangyi Bai
Journal:  Hum Vaccin Immunother       Date:  2021-10-06       Impact factor: 3.452

Review 8.  Core Fucosylation Regulates the Function of Pre-BCR, BCR and IgG in Humoral Immunity.

Authors:  Yuhan Sun; Xueying Li; Tiantong Wang; Wenzhe Li
Journal:  Front Immunol       Date:  2022-03-25       Impact factor: 7.561

9.  Monomeric IgA Antagonizes IgG-Mediated Enhancement of DENV Infection.

Authors:  Adam D Wegman; Hengsheng Fang; Alan L Rothman; Stephen J Thomas; Timothy P Endy; Michael K McCracken; Jeffrey R Currier; Heather Friberg; Gregory D Gromowski; Adam T Waickman
Journal:  Front Immunol       Date:  2021-11-24       Impact factor: 7.561

Review 10.  Vaccine-Associated Enhanced Disease and Pathogenic Human Coronaviruses.

Authors:  Cillian Gartlan; Tom Tipton; Francisco J Salguero; Quentin Sattentau; Andrew Gorringe; Miles W Carroll
Journal:  Front Immunol       Date:  2022-04-04       Impact factor: 8.786

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.